Genmab: Biotech Stock Fights Cancer, Surges Into Buy Zone

With investors rotating away from technology, it is a good time to look for opportunities in other areas. Genmab (GMAB) is a biotech stock that has rallied into a buy zone amid sharp earnings growth. The Danish firm develops antibody-based therapeutics for cancer and other serious diseases. The company has four major platforms that allow them to make antibodies which…